MEDEZE Group shows 2024 net profit at 338.74 MB, leaping 41.39% YOY with sweeping revenue at 897.22 MB, growing 25.78% after significant dealer and agent expansions to tackle increasing demands for stem cell storage. Moving in on the Philippines with Cell Banking Biotechnology establishment. Dividens 0.08 baht per share XD on 6 may 2025.

Dr. Veerapol Khemarangsann, Chief Executive Officer of MEDEZE Group Public Company Limited (MEDEZE), announced that the company recorded a net profit of 98.27 million baht in Q4 2024, or +3.79% QoQ and +78.28% YoY. While year 2024 net profit reached 338.74 million baht, a 41.39% increase from the previous year. The ex-dividend date is set for 6 May 2025, with dividend payments scheduled for May 22, 2025.

In Q4/2024, total revenue reached 246.57 million baht, up 5.37% QoQ and 28.80% YoY. However, revenue from sales and services declined QoQ due to a change in the company’s revenue recognition policy during 2024 from recognizing the entire amount upon service completion to recognizing revenue progressively over the service period. For the full year, revenues from sales and services totaled 829.21 million baht, increased 127.40 million baht or 18.15% compared to 2023.

The group’s robust and sustained growth in both total revenue and net profit aligns with its strategic targets. This performance is largely driven by the increasing global and domestic interest in its stem cell business as well as MEDEZE’s commitment in research and development and forging new partnerships to fuel business expansion and performance toward business stability, prosperity, and sustainability.

The revenue increase is primarily attributed overall to stem cell banking, especially for newborns which providing highly potent and resilient cells that are primed for future therapeutic use with the advancement of medical innovations and accredited reserches. Demand trend for stem cell storage is inreasing, and the expansion of the sales team and the recruitment of new business partners who are dealers and agents have significantly allowed broader reaches to customers seeking stem cell banking services. The growing network of medical professionals and healthcare institutions further supports the group’s continuous revenue growth.

Meanwhile, MEDEZE is advancing its biotechnology business in the Philippines through an investment by its subsidiary, MEDEZE Treasury PTE LTD. The company is establishing Cell Banking Biotechnology facility which consists of laboratories for stem cell analysis, sorting, culturing, and high-efficiency storage. This new facility is designed to meet the growing demand for stem cell banking services in the Philippines with promising expansion prospects.